ASH 2022 | Latest updates on momelotinib: safety, durability of response & survival benefit
Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on the updated results from the SIMPLIFY-1 (NCT01969838), SIMPLIFY-2 (NCT02101268), and MOMENTUM (NCT04173494) studies evaluating momelotinib in patients with myelofibrosis (MF). Data from these three studies reported a good durability of response, a benefit in survival, and a consistent safety profile for momelotinib, without any unexpected adverse events. In addition, it was shown that it is feasible to switch from danazol or ruxolitinib to momelotinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Geron: Membership on an entity’s Board of Directors or advisory committees; Keros: Consultancy; Constellation Pharmaceuticals, Inc., a MorphoSys Company: Membership on an entity’s Board of Directors or advisory committees, Research Funding; EHA: Other: Leadership role; MPN voice: Other: Leadership role; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Shire: Membership on an entity’s Board of Directors or advisory committees; Sierra: Honoraria; AOP Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Promedior: Membership on an entity’s Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Gilead: Membership on an entity’s Board of Directors or advisory committees; Janssen: Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees; Galecto: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees, Other: Support for attending meetings, Research Funding; Galacteo: Membership on an entity’s Board of Directors or advisory committees; Celgene/BMS: Membership on an entity’s Board of Directors or advisory committees, Research Funding.
